Mark A Dickson

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma
    Mark A Dickson
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 31:2024-8. 2013
  2. doi request reprint Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
    M A Dickson
    Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Oncol 24:252-7. 2013
  3. pmc Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates
    Mark A Dickson
    Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Cancer 132:1711-7. 2013
  4. pmc Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
    Gary K Schwartz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 14:371-82. 2013
  5. pmc The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial
    Jason J Luke
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Cancer Res 18:2638-47. 2012

Detail Information

Publications5

  1. pmc Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma
    Mark A Dickson
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 31:2024-8. 2013
    ..In a phase I trial of PD0332991, several patients with WDLS or DDLS experienced prolonged stable disease. We performed an open-label phase II study to determine the safety and efficacy of PD0332991 in patients with advanced WDLS/DDLS...
  2. doi request reprint Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
    M A Dickson
    Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Oncol 24:252-7. 2013
    ..BIIB021 is an oral non-ansamycin HSP90 inhibitor. We carried out a phase II study of BIIB021 in patients with GIST refractory to imatinib and sunitinib...
  3. pmc Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates
    Mark A Dickson
    Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Cancer 132:1711-7. 2013
    ..These findings highlight the consistent though incomplete activity of mTOR inhibitors in the treatment of PEComas...
  4. pmc Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
    Gary K Schwartz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 14:371-82. 2013
    ....
  5. pmc The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial
    Jason J Luke
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Cancer Res 18:2638-47. 2012
    ..As such, we explored the potentiation of doxorubicin by flavopiridol in sarcoma, in vitro and in vivo, and conducted a phase I trial of flavopiridol with doxorubicin in patients with advanced sarcomas...